BO
BOT.AU Botanix Pharmaceuticals Ltd
- Market cap
- AUD 27.6M
- P/E
- -
- P/B
- 0.43x
- ROE
- -109.8%
- Dividend yield
- -
- Fundamental score
- 1.4/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is BOT.AU undervalued?
Graham numberThe Graham number of Botanix Pharmaceuticals Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Botanix Pharmaceuticals Ltd fundamental analysis
6 of 21 checks passedROE 0/2
Low return on equity (-109.8%), below 10%.
ROA 0/1
Return on assets (-65.8%) is below the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (31.2%) is above the industry median (-5.3%).
Revenue Growth 2/2
Revenue grew 235.4% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (23.2%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.6 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.4x) is below the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Botanix Pharmaceuticals Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older. It also develops BTX 1503, a transdermal gel formulation, which is in Phase 3 clinical trial for the treatm…
Full company profileBotanix Pharmaceuticals Ltd financial statements
Botanix Pharmaceuticals Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 46.5K | 1.78M | 4.69M | 7.57M | 6.89M | 2.76M | 915K | 602K | 5.79M | 34.5M |
| Gross Profit | -3.65M | -9.26M | 4.68M | 7.47M | 316K | -7.54M | -3.05M | -6.12M | 2.02M | -59.4M |
| Operating Income | -8.38M | -22.1M | -21.8M | -29.5M | -10.3M | -15.9M | -12.8M | -15.7M | -80.8M | -69.3M |
| EBITDA | 33.2K | -1.48M | -17.2M | -24.1M | -10.1M | -15.7M | -12.6M | -15.3M | -80.7M | -69.3M |
| Net Income | -4.77M | -11.0M | -17.0M | -16.7M | -3.33M | -13.2M | -9.15M | -13.9M | -86.4M | -69.8M |
| EPS | -0.01 | -0.02 | -0.02 | -0.02 | 0.00 | -0.01 | -0.01 | -0.01 | -0.05 | -0.03 |
| Balance Sheet | ||||||||||
| Total Assets | 5.91M | 17.7M | 5.20M | 25.3M | 22.0M | 14.0M | 24.8M | 112M | 129M | 106M |
| Total Liabilities | 471K | 1.43M | 4.58M | 1.67M | 1.15M | 5.89M | 1.88M | 3.73M | 47.8M | 42.5M |
| Shareholders' Equity | 5.44M | 16.3M | 615K | 23.6M | 20.8M | 8.15M | 23.0M | 109M | 81.3M | 63.5M |
| Cash & Short-term Investments | 5.72M | 17.3M | 4.70M | 24.6M | 21.6M | 7.29M | 10.3M | 79.3M | 65.0M | 36.6M |
| Total Debt | - | - | 421K | 421K | 259K | 122K | - | - | 32.5M | 14.7M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -4.64M | -9.91M | -13.1M | -17.4M | -2.97M | -11.2M | -12.1M | -8.13M | -78.6M | -64.6M |
| Capital Expenditure | 13.3K | 13.3K | 13.3K | 90.1K | 8.28K | 2.92M | 7.05M | 18.0M | 286K | 3.00 |
| Free Cash Flow | -4.64M | -9.91M | -13.2M | -17.4M | -2.98M | -14.1M | -19.1M | -26.1M | -78.9M | -64.6M |
| Ratios | ||||||||||
| ROE | -87.8% | -67.6% | -2,769.6% | -70.8% | -16.0% | -161.6% | -39.9% | -12.8% | -106.3% | -109.8% |
| ROA | -80.8% | -62.2% | -327.7% | -66.1% | -15.2% | -93.8% | -36.9% | -12.3% | -66.9% | -65.8% |
| Net Profit Margin | -10,264.5% | -619.3% | -363.6% | -220.9% | -48.4% | -478.1% | -1,000.5% | -2,304.7% | -1,492.4% | -202.2% |
| Debt to Equity | - | - | 0.68x | 0.02x | 0.01x | 0.02x | - | - | 0.40x | 0.23x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Botanix Pharmaceuticals Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 1.32M | 0.00 | - |
| 2022 | AUD 20.3M | 0.02 | - |
| 2021 | - | - | - |
| 2020 | AUD 34.1M | 0.04 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | AUD 6.15M | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:3 on Jun 16, 2016.
Who owns Botanix Pharmaceuticals Ltd
- Insiders 11.49%
- Institutions 6.23%
- Public & others 82.28%
- Shares outstanding 2.76B
- Free float 2.44B
Botanix Pharmaceuticals Ltd company profile
- Company name
- Botanix Pharmaceuticals Ltd
- Ticker
- BOT.AU
- ISIN
- AU000000BOT2
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Tower 5, Collins Square, Melbourne, VIC, Australia, 3008
- Phone
- 61 8 6555 2945
- Website
- botanixpharma.com
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older. It also develops BTX 1503, a transdermal gel formulation, which is in Phase 3 clinical trial for the treatment of serious acne in adults and teenagers; BTX 1702 that is in Phase 1b/2 clinical trial to treat papulopustular rosacea; BTX 1204A for treating atopic dermatitis; and BTX 1801, which has been completed Phase 2a clinical trial for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus. The company was incorporated in 1984 and is based in Melbourne, Australia.
Botanix Pharmaceuticals Ltd management
7- Mr. Vincent P. IppolitoExecutive Chairman · born 1959
- Dr. Howie McKibbonChief Executive Officer
- Mr. Chris LesovitzChief Financial Officer of United States of America
- Mr. Paul SeabackChief Operating Officer
- Dr. Boris Meyerson Ph.D.Chief Business Officer
- Mr. David MorganHead of Corporate Affairs
- Mr. Darin Van ArsdaleDirector of Sales Operations